MedPage Today on MSN
Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke
N EW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse ...
It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.
Q3 2025 Earnings Call Transcript November 6, 2025 AMN Healthcare Services, Inc. beats earnings expectations. Reported EPS is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback